Literature DB >> 25187556

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.

Erinn B Rankin1, Katherine C Fuh1, Laura Castellini1, Kartik Viswanathan1, Elizabeth C Finger1, Anh N Diep1, Edward L LaGory1, Mihalis S Kariolis1, Andy Chan1, David Lindgren2, Håkan Axelson2, Yu R Miao1, Adam J Krieg3, Amato J Giaccia4.   

Abstract

Dysregulation of the von Hippel-Lindau/hypoxia-inducible transcription factor (HIF) signaling pathway promotes clear cell renal cell carcinoma (ccRCC) progression and metastasis. The protein kinase GAS6/AXL signaling pathway has recently been implicated as an essential mediator of metastasis and receptor tyrosine kinase crosstalk in cancer. Here we establish a molecular link between HIF stabilization and induction of AXL receptor expression in metastatic ccRCC. We found that HIF-1 and HIF-2 directly activate the expression of AXL by binding to the hypoxia-response element in the AXL proximal promoter. Importantly, genetic and therapeutic inactivation of AXL signaling in metastatic ccRCC cells reversed the invasive and metastatic phenotype in vivo. Furthermore, we define a pathway by which GAS6/AXL signaling uses lateral activation of the met proto-oncogene (MET) through SRC proto-oncogene nonreceptor tyrosine kinase to maximize cellular invasion. Clinically, AXL expression in primary tumors of ccRCC patients correlates with aggressive tumor behavior and patient lethality. These findings provide an alternative model for SRC and MET activation by growth arrest-specific 6 in ccRCC and identify AXL as a therapeutic target driving the aggressive phenotype in renal clear cell carcinoma.

Entities:  

Keywords:  VHL; hepatocellular carcinoma; kidney cancer; targeted therapy

Mesh:

Substances:

Year:  2014        PMID: 25187556      PMCID: PMC4169907          DOI: 10.1073/pnas.1404848111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  A renaissance for SRC.

Authors:  Timothy J Yeatman
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  Characterization of the invasive and metastatic phenotype in human renal cell carcinoma.

Authors:  I Saiki; S Naito; J Yoneda; I Azuma; J E Price; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1991 Nov-Dec       Impact factor: 5.150

3.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

5.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

6.  Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).

Authors:  P Longati; A Bardelli; C Ponzetto; L Naldini; P M Comoglio
Journal:  Oncogene       Date:  1994-01       Impact factor: 9.867

7.  Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia.

Authors:  G L Wang; G L Semenza
Journal:  J Biol Chem       Date:  1993-10-15       Impact factor: 5.157

8.  Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL.

Authors:  Peter Staller; Jitka Sulitkova; Joanna Lisztwan; Holger Moch; Edward J Oakeley; Wilhelm Krek
Journal:  Nature       Date:  2003-09-18       Impact factor: 49.962

9.  Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways.

Authors:  Yide Jiang; Wen Zhang; Keichii Kondo; Jeffery M Klco; Thia B St Martin; Michael R Dufault; Stephen L Madden; William G Kaelin; Mariana Nacht
Journal:  Mol Cancer Res       Date:  2003-04       Impact factor: 5.852

10.  Purification and characterization of hypoxia-inducible factor 1.

Authors:  G L Wang; G L Semenza
Journal:  J Biol Chem       Date:  1995-01-20       Impact factor: 5.157

View more
  121 in total

1.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

2.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

3.  Gas6 expression is reduced in advanced breast cancers.

Authors:  Ayman M Ibrahim; Zane Gray; Angelica M Gomes; Leann Myers; Fariba Behbod; Heather L Machado
Journal:  NPJ Precis Oncol       Date:  2020-04-24

Review 4.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

Review 5.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Authors:  Johannes Schödel; Steffen Grampp; Eamonn R Maher; Holger Moch; Peter J Ratcliffe; Paul Russo; David R Mole
Journal:  Eur Urol       Date:  2015-08-19       Impact factor: 20.096

Review 6.  Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Authors:  Manuela Schmidinger; Romano Danesi
Journal:  Oncologist       Date:  2017-11-16

7.  Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.

Authors:  Mihalis S Kariolis; Yu Rebecca Miao; Anh Diep; Shannon E Nash; Monica M Olcina; Dadi Jiang; Douglas S Jones; Shiven Kapur; Irimpan I Mathews; Albert C Koong; Erinn B Rankin; Jennifer R Cochran; Amato J Giaccia
Journal:  J Clin Invest       Date:  2016-11-28       Impact factor: 14.808

8.  Engineered AXL-ECD-Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration.

Authors:  Yanting Duan; Bo Hu; Chunxia Qiao; Longlong Luo; Xinying Li; Jing Wang; Hao Liu; Tingting Zhou; Beifen Shen; Ming Lv; Jiannan Feng
Journal:  Oncol Lett       Date:  2019-04-15       Impact factor: 2.967

9.  Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Authors:  Marguerite L Palisoul; Jeanne M Quinn; Emily Schepers; Ian S Hagemann; Lei Guo; Kelsey Reger; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2017-09-13       Impact factor: 6.261

10.  Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Authors:  David Cella; Bernard Escudier; Nizar M Tannir; Thomas Powles; Frede Donskov; Katriina Peltola; Manuela Schmidinger; Daniel Y C Heng; Paul N Mainwaring; Hans J Hammers; Jae Lyun Lee; Bruce J Roth; Florence Marteau; Paul Williams; John Baer; Milan Mangeshkar; Christian Scheffold; Thomas E Hutson; Sumanta Pal; Robert J Motzer; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2018-01-29       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.